Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.39 |
| ▸ | PPARG | P37231 | 7/20 | 0.39 |
| ▸ | PPARD | Q03181 | 7/20 | 0.39 |
| ▸ | PPARA | Q07869 | 7/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5611416 | 0.82 | FOLH1 (0.46) | FOLH1HSPD1BLMHSPE1AKR1B1 | |
| SCHEMBL9556833 | 0.82 | FOLH1 (0.46) | FOLH1HSPD1BLMHSPE1AKR1B1 | |
| SCHEMBL6297156 | 0.81 | HSPD1 (0.56) | HSPD1BLMHSPE1FFAR1GPR84 | |
| SCHEMBL11684679 | 0.81 | HSPD1 (0.44) | FOLH1HSPD1BLMHSPE1AKR1B1 | |
| SCHEMBL9749309 | 0.80 | FOLH1 (0.39) | FOLH1HSPD1BLMHSPE1AKR1B1 | |
| SCHEMBL1069110 | 0.79 | HSPD1 (0.39) | HSPD1BLMHSPE1FFAR1GPR84 | |
| SCHEMBL30219802 | 0.78 | FOLH1 (0.43) | FOLH1HSPD1BLMHSPE1TSHR | |
| Hydrochloric Acid SCHEMBL27599702 | 0.77 | FOLH1 (0.42) | FOLH1HSPD1BLMHSPE1HDAC11 | |
| SCHEMBL26679416 | 0.76 | LMNA (0.46) | HSPD1BLMHSPE1AKR1B1FFAR4 | |
| SCHEMBL1967834 | 0.76 | FOLH1 (0.41) | FOLH1HSPD1BLMHSPE1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002053621-A1 | ADVANCED RESIN DERIVED FROM A LOW MOLECULAR WEIGHT GLYCIDYL ETHER AND A DI-TERTIARY CARBOXYLIC ACID AND POWDER COATING COMPOSITIONS COMPRISING IT | RESOLUTION RESEARCH NEDERLAND B.V. (NL) | 2002-07-11 | — | — | WO | claimed |
| CN-108888590-A | The topical formulations of suspension type comprising tacrolimus | 江苏知原药业有限公司 | 2018-11-27 | — | — | CN | disclosed |
| EP-2699231-B1 | SUSPENSION TYPE TOPICAL FORMULATIONS COMPRISING CYCLIC DEPSIPEPTIDE | NOVARTIS AG (CH) | 2017-09-13 | — | — | EP | disclosed |
| US-9114110-B2 | Suspension type topical formulations comprising cyclic depdipeptide | NOVARTIS AG (CH) | 2015-08-25 | — | — | US | disclosed |
| CN-103476396-B | Suspension type topical formulation comprising cyclic depsipeptides | NOVARTIS AG (CH) | 2015-08-05 | — | — | CN | disclosed |
| US-20140162959-A1 | SUSPENSION TYPE TOPICAL FORMULATIONS COMPRISING CYCLIC DEPDIPEPTIDE | NOVARTIS AG (CH) | 2014-06-12 | — | — | US | disclosed |
| US-8680054-B2 | Suspension type topical formulations comprising cyclic depsipeptide | NOVARTIS AG (CH) | 2014-03-25 | — | — | US | disclosed |
| EP-2699231-A1 | SUSPENSION TYPE TOPICAL FORMULATIONS COMPRISING CYCLIC DEPSIPEPTIDE | Novartis AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| CN-103476396-A | Suspension type topical formulation comprising cyclic depsipeptides | NOVARTIS AG | 2013-12-25 | — | — | CN | disclosed |
| WO-2012143868-A1 | SUSPENSION TYPE TOPICAL FORMULATIONS COMPRISING CYCLIC DEPSIPEPTIDE | NOVARTIS AG (CH) | 2012-10-26 | — | — | WO | disclosed |
| US-20120270796-A1 | Suspension Type Topical Formulations Comprising Cyclic Depsipeptide | NOVARTIS AG (CH) | 2012-10-25 | — | — | US | disclosed |
| WO-2002053621-A1 | ADVANCED RESIN DERIVED FROM A LOW MOLECULAR WEIGHT GLYCIDYL ETHER AND A DI-TERTIARY CARBOXYLIC ACID AND POWDER COATING COMPOSITIONS COMPRISING IT | RESOLUTION RESEARCH NEDERLAND B.V. (NL) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002036700-A1 | CURABLE POWDER COATING COMPRISING COPOLYMERS OF AT LEAST ALKYLESTERS AND AN EPOXY ALKYLESTER | RESOLUTION RESEARCH NEDERLAND B.V. (NL) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270796-A1 | Suspension Type Topical Formulations Comprising Cyclic Depsipeptide | LPXN, PSAP, PDE7B | FOLH1 439/4885HSPD1 4694/4885BLM 3761/4885 |
| US-20140162959-A1 | SUSPENSION TYPE TOPICAL FORMULATIONS COMPRISING CYCLIC DEPDIPEPTIDE | LPXN, PDE7B, PSAP | FOLH1 471/4885HSPD1 4541/4885BLM 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.